About me
Richard Wilson, Senior Vice President, Primary Focus Lead of Genetic Regulation at Astellas Gene Therapies, is responsible for setting and leading the gene therapy strategy for Astellas’ Primary Focus Genetic Regulation. Richard joined Astellas Gene Therapies (formerly Audentes Therapeutics) in April 2020 as Vice President, Program Management. Richard has over 30 years of experience in research, development, and commercialization of small molecules, biological and gene therapies. Richard holds a BSc (Hons) in Chemistry from the University of Manchester and an MBA from the Haas School of Business at the University of California, Berkeley.
